Restrictive clearance models treat plasma protein binding as a determinant of hepatic drug uptake. Because only unbound drug can cross the sinusoidal membrane, changes in the unbound fraction alter the amount presented to metabolic enzymes. This links binding changes directly to potential changes in elimination and drug exposure, rather than relying on total plasma concentration alone.
Three variables are central: the unbound drug fraction, intrinsic metabolic capacity, and hepatic blood flow. The unbound fraction governs access to the liver, intrinsic capacity represents the liver’s ability to transform the drug, and blood flow describes delivery to the organ. Considering these factors together helps explain why altered protein binding, liver function, enzyme activity, or perfusion can change exposure.
The framework provides a way to compare medicines according to how their clearance relates to unbound availability, intrinsic metabolic capacity, and hepatic blood flow. Applying the same model to low- and high-extraction drugs helps pharmacology researchers interpret differences in predicted elimination and exposure, especially when protein binding, enzyme activity, liver function, or perfusion changes.
Researchers examine whether an interaction could change plasma protein binding, hepatic enzyme activity, liver function, or hepatic blood flow. The model then helps connect that change with altered unbound availability, metabolic capacity, or organ delivery. This approach supports interpretation of why a coadministered treatment might modify drug elimination and consequently change drug exposure.
Clinicians should consider factors that influence the model’s three main determinants: the unbound fraction, intrinsic metabolic capacity, and hepatic blood flow. Relevant changes may include altered protein binding, liver function, enzyme activity, or hepatic perfusion. Reviewing these variables helps clinicians anticipate changes in exposure and determine whether dosing interpretation may require adjustment.
Restrictive-clearance analysis can help predict how changes in binding, metabolism, or hepatic perfusion may affect drug exposure. It also allows researchers to compare the behavior of low- and high-extraction medicines within a common pharmacokinetic framework. These predictions support drug interaction studies, clinical pharmacology investigations, and interpretation of differing elimination patterns.